Literature DB >> 19010087

A liquid chromatography mass spectrometry assay for determination of PD168393, a specific and irreversible inhibitor of erbB membrane tyrosine kinases, in rat serum.

Jeevan K Prasain1, Alireza Arabshahi, Ray Moore, Stephen Barnes, Steven L Carroll.   

Abstract

For the first time, a rapid, sensitive and simple liquid chromatography/tandem mass spectrometry (LC-MS/MS) method using an atmospheric pressure chemical ionization (APCI) source for the quantification of PD168393 in rat serum was developed and validated. Serum samples were pretreated with methanol for protein precipitation. The chromatographic separation was performed on a Jupiter-C5 column (250 mm x 2.0 mm i.d.) pre-equilibrated with 0.1% formic acid. The tandem mass spectrometer was tuned in the multiple reaction monitoring mode to monitor the m/z transitions 369/313 for PD168393 and m/z 343/308 for the internal standard triazolam, using positive ion mode. The MS/MS response was linear over the concentration range from 2 ng/mL to 5000 ng/mL, with a lower limit of quantification (LLQ) of 2 ng/mL. At the lowest quality control (4 ng/mL), the intra- and inter-day precisions (CV%) for PD168393 were less than 10% and the accuracies were between 92% and 111%. The validated method can be used in most or all stages of the screening and optimizing process for future method validation of pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010087      PMCID: PMC2785089          DOI: 10.1016/j.jchromb.2008.10.046

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  12 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Matrix effects during analysis of plasma samples by electrospray and atmospheric pressure chemical ionization mass spectrometry: practical approaches to their elimination.

Authors:  Joachim Schuhmacher; Dieter Zimmer; Frank Tesche; Volker Pickard
Journal:  Rapid Commun Mass Spectrom       Date:  2003       Impact factor: 2.419

3.  Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.

Authors:  Yeong-Shiau Pu; Min-Wei Hsieh; Chuang-Wei Wang; Guang-Yaw Liu; Chao-Yuan Huang; Chia-Chi Lin; Jing-Yi Guan; Shinne-Ren Lin; Tzyh-Chyuan Hour
Journal:  Biochem Pharmacol       Date:  2006-01-18       Impact factor: 5.858

Review 4.  Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.

Authors:  D W Fry
Journal:  Pharmacol Ther       Date:  1999 May-Jun       Impact factor: 12.310

5.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Authors:  F M Sirotnak; M F Zakowski; V A Miller; H I Scher; M G Kris
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

6.  Phosphoproteomic analysis of Her2/neu signaling and inhibition.

Authors:  Ron Bose; Henrik Molina; A Scott Patterson; John K Bitok; Balamurugan Periaswamy; Joel S Bader; Akhilesh Pandey; Philip A Cole
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-19       Impact factor: 11.205

7.  Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors.

Authors:  Mark S Stonecypher; Stephanie J Byer; William E Grizzle; Steven L Carroll
Journal:  Oncogene       Date:  2005-08-25       Impact factor: 9.867

8.  Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation.

Authors:  Dalila Darmoul; Valérie Gratio; Hélène Devaud; Franck Peiretti; Marc Laburthe
Journal:  Mol Cancer Res       Date:  2004-09       Impact factor: 5.852

9.  Simultaneous determination of Aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection.

Authors:  C M Chavez-Eng; M L Constanzer; B K Matuszewski
Journal:  J Pharm Biomed Anal       Date:  2004-09-03       Impact factor: 3.935

10.  Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

Authors:  D W Fry; A J Bridges; W A Denny; A Doherty; K D Greis; J L Hicks; K E Hook; P R Keller; W R Leopold; J A Loo; D J McNamara; J M Nelson; V Sherwood; J B Smaill; S Trumpp-Kallmeyer; E M Dobrusin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

View more
  1 in total

1.  Epidermal growth factor receptor inhibitor ameliorates excessive astrogliosis and improves the regeneration microenvironment and functional recovery in adult rats following spinal cord injury.

Authors:  Zai-Wang Li; Ji-Jun Li; Lan Wang; Jian-Ping Zhang; Jing-Jing Wu; Xu-Qiang Mao; Guo-Feng Shi; Qian Wang; Feng Wang; Jian Zou
Journal:  J Neuroinflammation       Date:  2014-04-05       Impact factor: 8.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.